News

Under the cooperative R&D agreement, the collaboration will leverage Calibrant’s unique proteomic technologies for the purposes of evaluating and validating protein markers for a variety of major, unmet

This is the second agreement between 3M Health Care and Greystone Pharmaceuticals. The first agreement provided 3M Health Care distribution rights in Canada and parts of Europe. This

Under the terms of the agreement, PTC will commercialize PTC124 in the US and Canada, and Genzyme will commercialize the treatment in all other countries. Genzyme will make

According to the company, the Sonatherm 600i system will be used to ablate certain soft tissue lesions, excluding the prostate gland, in general surgery. The company expects to

This is the initial acquisition for Dynova Laboratories, a new company with expertise in identifying and building successful over-the-counter (OTC) brands. Dynova’s objective is to bring to market

Schering-Plough’s Nasonex is an intranasal steroid that significantly improves nasal allergy symptoms when taken once each day. Nasonex is said to be the first intranasal steroid to be

In this position, Dr Bedigian will take the lead and be responsible for all medical aspects of Isis’s clinical development programs. Dr Bedigian comes to Isis from Novartis

Recombinant aflatoxin detoxifizyme (rADTZ) is said to be an innovative product that has the potential to detoxify aflatoxin (AFT), a potential cancer causing agent, in food and feed.

This multicenter, randomized, double-blind, dose-escalating, placebo-controlled study is evaluating the safety, tolerability, efficacy, and pharmacokinetics of a single dose of Adlea administered via injection following surgical closure of